Merck EBITDA Margin 2006-2020 | MRK

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Merck (MRK) over the last 10 years. The current EBITDA margin for Merck as of March 31, 2020 is .
Merck EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2020-03-31 $48.08B $16.39B 34.09%
2019-12-31 $46.84B $15.89B 33.93%
2019-09-30 $45.97B $16.05B 34.90%
2019-06-30 $44.37B $16.35B 36.84%
2019-03-31 $43.07B $15.47B 35.92%
2018-12-31 $42.29B $13.45B 31.80%
2018-09-30 $41.73B $12.80B 30.68%
2018-06-30 $41.26B $10.35B 25.07%
2018-03-31 $40.73B $10.48B 25.74%
2017-12-31 $40.12B $11.47B 28.60%
2017-09-30 $39.80B $8.46B 21.26%
2017-06-30 $40.02B $11.41B 28.51%
2017-03-31 $39.93B $10.92B 27.35%
2016-12-31 $39.81B $10.97B 27.56%
2016-09-30 $39.91B $14.29B 35.80%
2016-06-30 $39.44B $13.95B 35.37%
2016-03-31 $39.39B $14.09B 35.78%
2015-12-31 $39.50B $13.92B 35.25%
2015-09-30 $39.77B $13.51B 33.97%
2015-06-30 $40.25B $12.91B 32.08%
2015-03-31 $41.40B $12.72B 30.73%
2014-12-31 $42.24B $13.37B 31.66%
2014-09-30 $43.08B $14.13B 32.79%
2014-06-30 $43.55B $14.99B 34.41%
2014-03-31 $43.63B $14.97B 34.31%
2013-12-31 $44.03B $14.65B 33.28%
2013-09-30 $44.45B $14.43B 32.46%
2013-06-30 $44.91B $14.35B 31.96%
2013-03-31 $46.21B $15.80B 34.19%
2012-12-31 $47.27B $16.86B 35.66%
2012-09-30 $47.82B $17.09B 35.73%
2012-06-30 $48.36B $17.27B 35.72%
2012-03-31 $48.20B $16.92B 35.11%
2011-12-31 $48.05B $16.40B 34.14%
2011-09-30 $47.85B $13.97B 29.20%
2011-06-30 $46.95B $12.99B 27.67%
2011-03-31 $46.15B $12.15B 26.32%
2010-12-31 $45.99B $10.74B 23.35%
2010-09-30 $43.99B $10.33B 23.48%
2010-06-30 $38.91B $9.06B 23.28%
2010-03-31 $33.47B $7.58B 22.65%
2009-12-31 $27.43B $6.60B 24.06%
2009-09-30 $23.37B $7.37B 31.54%
2009-06-30 $23.26B $7.29B 31.35%
2009-03-31 $23.41B $7.31B 31.23%
2008-12-31 $23.85B $7.72B 32.35%
2008-09-30 $24.06B $8.03B 33.35%
2008-06-30 $24.19B $7.72B 31.92%
2008-03-31 $24.25B $7.74B 31.90%
2007-12-31 $24.20B $7.61B 31.43%
2007-09-30 $24.00B $6.36B 26.50%
2007-06-30 $23.33B $5.82B 24.94%
2007-03-31 $23.00B $5.83B 25.37%
2006-12-31 $22.64B $5.96B 26.31%
2006-09-30 $22.36B $6.65B 29.74%
2006-06-30 $22.36B $7.53B 33.68%
2006-03-31 $22.06B $7.58B 34.37%
2005-12-31 $22.01B $7.57B 34.38%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $207.633B $46.840B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.076B 16.59
Roche Holding AG (RHHBY) Switzerland $294.143B 0.00
Pfizer (PFE) United States $199.918B 12.41
Novartis AG (NVS) Switzerland $196.843B 15.36
Novo Nordisk (NVO) Denmark $151.861B 25.29
Eli Lilly (LLY) United States $142.712B 23.10
AstraZeneca (AZN) United Kingdom $141.323B 29.11
Bristol-Myers Squibb (BMY) United States $138.771B 11.59
AbbVie (ABBV) United States $138.592B 10.18
Sanofi (SNY) $125.457B 14.52
GlaxoSmithKline (GSK) United Kingdom $104.605B 12.49
Bayer (BAYRY) Germany $69.270B 9.88
H Lundbeck (HLUYY) Denmark $8.181B 14.21
Innoviva (INVA) United States $1.408B 8.13